Celltrion applies sales approval of Herzuma to enter Japanese market

Published: 2017-04-14 16:26:00
Updated: 2017-04-14 14:42:59

Celltrion announced it applied sales approval of Herzuma(CT-P6, generic name: trastuzumab), a self-developed anticancer antibody biosimilar, at the Japanese Ministry of Health, Labour and Welfare on the 11th to enter the Japanese market.

Herzuma, an anticancer antibody biosimilar used to treat b...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.